Optimal Further Strengthens Operations with New Global Sales Manager, Chris Vickers

Optimal further strengthens operations with new global sales manager

Process Analytical Technology (PAT) leader, Optimal Industrial Technologies, is increasing its support for the growing global demand for data-driven, automated process control strategies with the appointment of Chris Vickers. As global sales manager, he will be responsible for creating new business opportunities while continuing to serve existing customers, enhancing the company’s ability to deliver unparalleled value.

As a leading specialist in PAT and creator of the award-winning, market-leading software, synTQ, Optimal is committed to helping its customers realise the benefits of advanced analytics and real-time process monitoring. In essence, the company aims to drive the competitiveness of organisations across industry and around the world in the digital era. The addition of Chris Vickers to the team signifies the Optimal’s dedication to exceeding customer expectations through high-quality, comprehensive support.

With over 38 years of experience in sales leadership and a profound understanding of the instrumentation and control sector, Chris Vickers possesses the vision and strategic acumen necessary to guide Optimal’s customers to new heights. By leveraging his expertise in both highly regulated and fast-paced reactive industries, the new global sales manager will be instrumental in ensuring that every customer benefits from solutions tailored to their specific requirements, ultimately enabling them to optimise their processes and enhance operational efficiency.

Martin Gadsby, VP at Optimal, comments: “In addition to manufacturers looking to adopt PAT, we are seeing global customers interested in expanding their PAT-driven frameworks to improve multiple lines and plants. Chris Vickers has a proven ability to engage with experts in a variety of industries and intuitively understand their requirements. These capabilities make him the ideal candidate to strengthen existing customer relationships and forge new collaborations. We are extremely delighted to have him on our team and excited to see what we can achieve together.”

Chris Vickers concludes: “I am honoured to join Optimal and be part of an organisation that is at the forefront of PAT and enabling technologies for smart manufacturing. synTQ can help companies gain unparalleled advantages, from driving profitability to shortening time-to-market and improving efficiency while reducing waste. I’d like to invite anyone interested in joining the ranks of the industry leaders who are already using PAT and synTQ to address bottlenecks, transform their businesses and stay ahead of the competition to get in touch with me. I look forward to developing the right solution for you!”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version